You have free access to this content

Value in Health

Cover image for Vol. 13 Issue 1

January/February 2010

Volume 13, Issue 1

Pages viii–viii, 1–158

  1. ISPOR Code of Ethics

    1. Top of page
    2. ISPOR Code of Ethics
    3. EDITORIALS
    4. SCIENTIFIC TASK FORCE REPORTS
    5. ECONOMIC EVALUATION
    6. OUTCOMES ASSESSMENT
    7. POLICY ANALYSIS
    8. LETTERS TO THE EDITOR / CORRESPONDANCE
    9. ERRATUM
    1. You have free access to this content
      ISPOR CODE OF ETHICS : MARCH 2008 (page viii)

      Version of Record online: 17 DEC 2009 | DOI: 10.1111/j.1524-4733.2009.00496.x

  2. EDITORIALS

    1. Top of page
    2. ISPOR Code of Ethics
    3. EDITORIALS
    4. SCIENTIFIC TASK FORCE REPORTS
    5. ECONOMIC EVALUATION
    6. OUTCOMES ASSESSMENT
    7. POLICY ANALYSIS
    8. LETTERS TO THE EDITOR / CORRESPONDANCE
    9. ERRATUM
    1. You have free access to this content
      Beyond AWP . . . Way Beyond (page 1)

      Richard J. Willke

      Version of Record online: 12 NOV 2009 | DOI: 10.1111/j.1524-4733.2009.00673.x

    2. You have free access to this content
      What's in a Perspective? (page 2)

      Henry A. Glick

      Version of Record online: 12 NOV 2009 | DOI: 10.1111/j.1524-4733.2009.00674.x

  3. SCIENTIFIC TASK FORCE REPORTS

    1. Top of page
    2. ISPOR Code of Ethics
    3. EDITORIALS
    4. SCIENTIFIC TASK FORCE REPORTS
    5. ECONOMIC EVALUATION
    6. OUTCOMES ASSESSMENT
    7. POLICY ANALYSIS
    8. LETTERS TO THE EDITOR / CORRESPONDANCE
    9. ERRATUM
    1. You have free access to this content
      Good Research Practices for Measuring Drug Costs in Cost Effectiveness Analyses: Issues and Recommendations: The ISPOR Drug Cost Task Force Report—Part I (pages 3–7)

      Joel W. Hay, Jim Smeeding, Norman V. Carroll, Michael Drummond, Louis P. Garrison, Edward C. Mansley, C. Daniel Mullins, Jack M. Mycka, Brian Seal and Lizheng Shi

      Version of Record online: 28 OCT 2009 | DOI: 10.1111/j.1524-4733.2009.00663.x

    2. You have free access to this content
      Good Research Practices for Measuring Drug Costs in Cost-Effectiveness Analyses: A Societal Perspective: The ISPOR Drug Cost Task Force Report—Part II (pages 8–13)

      Louis P. Garrison Jr., Edward C. Mansley, Thomas A. Abbott III, Brian W. Bresnahan, Joel W. Hay and James Smeeding

      Version of Record online: 26 OCT 2009 | DOI: 10.1111/j.1524-4733.2009.00660.x

    3. You have free access to this content
      Good Research Practices for Measuring Drug Costs in Cost-Effectiveness Analyses: A Managed Care Perspective: The ISPOR Drug Cost Task Force Report—Part III (pages 14–17)

      Edward C. Mansley, Norman V. Carroll, Kristina S. Chen, Nilay D. Shah, Catherine Tak Piech, Joel W. Hay and James Smeeding

      Version of Record online: 26 OCT 2009 | DOI: 10.1111/j.1524-4733.2009.00661.x

    4. You have free access to this content
      Good Research Practices for Measuring Drug Costs in Cost-Effectiveness Analyses: Medicare, Medicaid and Other US Government Payers Perspectives: The ISPOR Drug Cost Task Force Report—Part IV (pages 18–24)

      C. Daniel Mullins, Brian Seal, Enrique Seoane-Vazquez, Jayashri Sankaranarayanan, Carl V. Asche, Ravishankar Jayadevappa, Won Chan Lee, Dorothy K. Romanus, Junling Wang, Joel W. Hay and Jim Smeeding

      Version of Record online: 6 OCT 2009 | DOI: 10.1111/j.1524-4733.2009.00604.x

    5. You have free access to this content
      Good Research Practices for Measuring Drug Costs in Cost Effectiveness Analyses: An Industry Perspective: The ISPOR Drug Cost Task Force Report—Part V (pages 25–27)

      Jack M. Mycka, Renato Dellamano, Eugene Mick Kolassa, Michael Wonder, Sabyasachi Ghosh, Joel W. Hay and Jim Smeeding

      Version of Record online: 26 OCT 2009 | DOI: 10.1111/j.1524-4733.2009.00664.x

    6. You have free access to this content
      Good Research Practices for Measuring Drug Costs in Cost-Effectiveness Analyses: An International Perspective: The ISPOR Drug Cost Task Force Report—Part VI (pages 28–33)

      Lizheng Shi, Meredith Hodges, Michael Drummond, Jeonghoon Ahn, Shu Chuen Li, Shanlian Hu, Federico Augustovski, Joel W. Hay and Jim Smeeding

      Version of Record online: 26 OCT 2009 | DOI: 10.1111/j.1524-4733.2009.00662.x

  4. ECONOMIC EVALUATION

    1. Top of page
    2. ISPOR Code of Ethics
    3. EDITORIALS
    4. SCIENTIFIC TASK FORCE REPORTS
    5. ECONOMIC EVALUATION
    6. OUTCOMES ASSESSMENT
    7. POLICY ANALYSIS
    8. LETTERS TO THE EDITOR / CORRESPONDANCE
    9. ERRATUM
    1. You have free access to this content
      The Multinational Nature of Cost-Effectiveness Analyses Alongside Multinational Clinical Trials (pages 34–41)

      Oliver Rivero-Arias and Alastair Gray

      Version of Record online: 17 DEC 2009 | DOI: 10.1111/j.1524-4733.2009.00582.x

    2. You have free access to this content
      Cost–Benefit Analysis of Preventing Nosocomial Bloodstream Infections among Hemodialysis Patients in Canada in 2004 (pages 42–45)

      Zhiyong Hong, Jun Wu, Clem Tisdell, Crystal O'Leary, James Gomes, Shi-Wu Wen and Howard Njoo

      Version of Record online: 29 JUL 2009 | DOI: 10.1111/j.1524-4733.2009.00578.x

    3. You have free access to this content
      The Impact of Fewer Hip Fractures with Risedronate Versus Alendronate in the First Year of Treatment: Modeled German Cost-Effectiveness Analysis (pages 46–54)

      Melissa Thompson, Margaret Pasquale, Daniel Grima, Werner Moehrke and Hans Peter Kruse

      Version of Record online: 26 OCT 2009 | DOI: 10.1111/j.1524-4733.2009.00666.x

    4. You have free access to this content
      Cost-Effectiveness of Sorafenib for Second-Line Treatment of Advanced Renal Cell Carcinoma (pages 55–60)

      Martin Hoyle, Colin Green, Jo Thompson-Coon, Zulian Liu, Karen Welch, Tiffany Moxham and Ken Stein

      Version of Record online: 25 SEP 2009 | DOI: 10.1111/j.1524-4733.2009.00616.x

    5. You have free access to this content
      Cost-Effectiveness of Temsirolimus for First Line Treatment of Advanced Renal Cell Carcinoma (pages 61–68)

      Martin Hoyle, Colin Green, Jo Thompson-Coon, Zulian Liu, Karen Welch, Tiffany Moxham and Ken Stein

      Version of Record online: 25 SEP 2009 | DOI: 10.1111/j.1524-4733.2009.00617.x

    6. You have free access to this content
      Budget Impact Analysis of Thrombolysis for Stroke in Spain: A Discrete Event Simulation Model (pages 69–76)

      Javier Mar, Arantzazu Arrospide and Mercè Comas

      Version of Record online: 8 OCT 2009 | DOI: 10.1111/j.1524-4733.2009.00655.x

    7. You have free access to this content
      Prevalence of Respiratory Syncytial Virus (RSV) Risk Factors and Cost Implications of Immunoprophylaxis to Infants 32 to 35 Weeks Gestation for Health Plans in the United States (pages 77–86)

      Leonard R. Krilov, Debra L. Palazzi, Ancilla W. Fernandes, Robert W. Klein and Parthiv J. Mahadevia

      Version of Record online: 24 AUG 2009 | DOI: 10.1111/j.1524-4733.2009.00586.x

    8. You have free access to this content
      Relationship between Adherence Level to Statins, Clinical Issues and Health-Care Costs in Real-Life Clinical Setting (pages 87–94)

      Alice Dragomir, Robert Côté, Michel White, Lyne Lalonde, Lucie Blais, Anick Bérard and Sylvie Perreault

      Version of Record online: 20 AUG 2009 | DOI: 10.1111/j.1524-4733.2009.00583.x

  5. OUTCOMES ASSESSMENT

    1. Top of page
    2. ISPOR Code of Ethics
    3. EDITORIALS
    4. SCIENTIFIC TASK FORCE REPORTS
    5. ECONOMIC EVALUATION
    6. OUTCOMES ASSESSMENT
    7. POLICY ANALYSIS
    8. LETTERS TO THE EDITOR / CORRESPONDANCE
    9. ERRATUM
    1. You have free access to this content
      Relationship between Health-Related Quality of Life, Pain, and Functional Disability in Neuropathic Pain Patients with Failed Back Surgery Syndrome (pages 95–102)

      Andrea Manca, Sam Eldabe, Eric Buchser, Krishna Kumar and Rod S. Taylor

      Version of Record online: 20 AUG 2009 | DOI: 10.1111/j.1524-4733.2009.00588.x

    2. You have free access to this content
      A Multinational Study of Health State Preference Values Associated with Chronic Myelogenous Leukemia (pages 103–111)

      Shelagh M. Szabo, Adrian R. Levy, Catherine Davis, Tessa L. Holyoake and Jorge Cortes

      Version of Record online: 29 JUL 2009 | DOI: 10.1111/j.1524-4733.2009.00573.x

    3. You have free access to this content
      Patient Characteristics Impacting Health State Index Scores, Measured by the EQ-5D of Females with Stress Urinary Incontinence Symptoms (pages 112–118)

      Douglas Tincello, Mark Sculpher, Ralf Tunn, Deborah Quail, Huub Van Der Vaart, Christian Falconer, Martina Manning and Louise Timlin

      Version of Record online: 10 SEP 2009 | DOI: 10.1111/j.1524-4733.2009.00599.x

    4. You have free access to this content
    5. You have free access to this content
      A Methodology for Successfully Producing Global Translations of Patient Reported Outcome Measures for Use in Multiple Countries (pages 128–131)

      Rebecca Two, Aneesa Verjee-Lorenz, Darren Clayson, Mehul Dalal, Kelly Grotzinger and Zobair M Younossi

      Version of Record online: 20 AUG 2009 | DOI: 10.1111/j.1524-4733.2009.00585.x

    6. You have free access to this content
      Instrumental Variables in Influenza Vaccination Studies: Mission Impossible?! (pages 132–137)

      Rolf H. H. Groenwold, Eelko Hak, Olaf H. Klungel and Arno W. Hoes

      Version of Record online: 20 AUG 2009 | DOI: 10.1111/j.1524-4733.2009.00584.x

  6. POLICY ANALYSIS

    1. Top of page
    2. ISPOR Code of Ethics
    3. EDITORIALS
    4. SCIENTIFIC TASK FORCE REPORTS
    5. ECONOMIC EVALUATION
    6. OUTCOMES ASSESSMENT
    7. POLICY ANALYSIS
    8. LETTERS TO THE EDITOR / CORRESPONDANCE
    9. ERRATUM
    1. You have free access to this content
      Relationships among Self-Management, Patient Perceptions of Care, and Health Economic Outcomes for Decision-Making and Clinical Practice in Type 2 Diabetes (pages 138–147)

      David S. Cobden, Louis W. Niessen, Charles E. Barr, Frans F. H. Rutten and W. Ken Redekop

      Version of Record online: 20 AUG 2009 | DOI: 10.1111/j.1524-4733.2009.00587.x

    2. You have free access to this content
      The Impact of Pharmaceutical Cost Containment Policies on the Range of Medicines Available and Subsidized in Finland and New Zealand (pages 148–156)

      Katri Aaltonen, Rajan Ragupathy, June Tordoff, David Reith and Pauline Norris

      Version of Record online: 10 SEP 2009 | DOI: 10.1111/j.1524-4733.2009.00598.x

  7. LETTERS TO THE EDITOR / CORRESPONDANCE

    1. Top of page
    2. ISPOR Code of Ethics
    3. EDITORIALS
    4. SCIENTIFIC TASK FORCE REPORTS
    5. ECONOMIC EVALUATION
    6. OUTCOMES ASSESSMENT
    7. POLICY ANALYSIS
    8. LETTERS TO THE EDITOR / CORRESPONDANCE
    9. ERRATUM
    1. You have free access to this content
      Calibration of Disease Simulation Model Using an Engineering Approach (page 157)

      Tazio Vanni, Rosa Legood and Richard G. White

      Version of Record online: 26 OCT 2009 | DOI: 10.1111/j.1524-4733.2009.00659.x

  8. ERRATUM

    1. Top of page
    2. ISPOR Code of Ethics
    3. EDITORIALS
    4. SCIENTIFIC TASK FORCE REPORTS
    5. ECONOMIC EVALUATION
    6. OUTCOMES ASSESSMENT
    7. POLICY ANALYSIS
    8. LETTERS TO THE EDITOR / CORRESPONDANCE
    9. ERRATUM
    1. You have free access to this content
      Erratum (page 158)

      Version of Record online: 17 DEC 2009 | DOI: 10.1111/j.1524-4733.2009.00682.x

      This article corrects:

      RESEARCH POSTER ABSTRACTS

      Vol. 12, Issue 7, A237–A460, Version of Record online: 15 SEP 2009

SEARCH

SEARCH BY CITATION